Latest News

IgAN Therapies: Can Success Signal New Challenges for Clinical Trials?

Will new treatments decrease potential participants for ongoing and future research? In a world where more efficient and better targeted treatments are being approved at an unprecedented rate, patients are understandably eager to take advantage of the new discoveries, especially when it comes to rare diseases such as Immunoglobulin A nephropathy (IgAN) where safe and […]

Read More

October 23rd, 2023

Omico Brings Cutting Edge Technology Earlier in the Clinical Research Process

Omico Will Precisely Match Patients to George Clinical Oncology Trials SYDNEY, July 28, 2023 – George Clinical recognises and applauds its collaborative partner Omico, with whom it is aligned in a common goal to revolutionize oncology clinical trial access for patients and improve the efficiency of study enrollment, on the launch of their landmark program […]

Read More

July 27th, 2023

2023 ASCO Celebrates Patients at the Cornerstone of Cancer Care and Research

Patient-centricity is the key to more successful research and adoption of new treatments. ASCO’s 2023 Annual Meeting drew oncology professionals from around the world to learn about new clinical advances in cancer research, gain real-time insights from world-renowned experts and connect with one of the largest, most diverse audiences in global oncology. Peer-to-peer interaction is the […]

Read More

July 12th, 2023

George Clinical Partners with Medidata to Unlock Operational Efficiency in Clinical Trials

Medidata, a Dassault Systèmes company, recently announced George Clinical is implementing Medidata’s cloud-based clinical solutions – Rave Grants Manager – to improve tracking and management of budgets. Medidata’s solution will also empower George Clinical to bring operational efficiency and improve patient recruitment by sites. The implementation will give George Clinical’s global clients the usage of […]

Read More

July 10th, 2023

George Clinical and EPS Collaborate on Important HR+/HER2- Breast Cancer Study in Asia Pacific

SYDNEY, June 27, 2023 – George Clinical and EPS Corporation (EPS), a global CRO based in Japan are collaborating on a rare Japanese academia-led global study seeking to advance treatments for unmet needs in Asian populations. In 2019 George Clinical and EPS formed a strategic partnership to help expand their operations across the Asia-Pacific region. […]

Read More

June 27th, 2023

Emerging Countries Offer Access to Diverse Patient Populations, Cost Savings and the Opportunity to Advance Equity in Clinical Research

Having recently attended the World Congress of Nephrology (WCN) in Bangkok, Thailand, George Clinical representatives had the opportunity to meet experts and peers from around the world to share ideas and best practices and continue to develop networks that will advance global kidney health. Connecting with communities from different parts of the world not only highlights […]

Read More

June 21st, 2023

George Clinical Wins Clinical Research Team of the Year from Citeline

George Clinical recently received the award for Clinical Research Team of the Year at the 7th Annual Citeline Awards held in Boston, MA.  As a 2023 winner, the George Clinical team won recognition for a multi-site program in the Asia Pacific region that recruited more than 3,000 patients across 14 sites in just seven weeks. […]

Read More

May 12th, 2023

George Clinical Applauded by Frost & Sullivan for Its Competitive Differentiation and Leadership in Strategy Execution in the Asia Pacific region

Frost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. George Clinical is a global CRO with world class expertise in kidney research, oncology and neurology and remains fully committed to growing their strong presence in Asia-Pacific which is where the company has […]

Read More

May 12th, 2023

George Clinical Selected as CRO for Hummingbird Bioscience’s Phase 1 Oncology Trials in Australia

SYDNEY, May 4, 2023 – George Clinical announces that the company has initiated preparations in Australia for two oncology Phase 1b trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer. George Clinical is providing […]

Read More

May 4th, 2023

Biomarkers Will Drive Future Diagnosis and Treatment of Kidney Disease

A deeper understanding of disease mechanisms will help address a growing global problem. Chronic kidney disease (CKD) is a global health crisis with an estimated 850 million people affected worldwide. Rising faster than all non-infectious diseases including cardiovascular disease, CKD is 20 times more prevalent than cancer. Most people don’t even realize their kidneys are […]

Read More

March 24th, 2023

Add George Clinical to your network